Effects of Biologic Therapy on Cardiovascular Disease in Psoriasis
- 13 January 2018
- journal article
- research article
- Published by Springer Nature in Current Dermatology Reports
- Vol. 7 (1) , 37-42
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Effects of the Tumor Necrosis Factor-α Antagonist Adalimumab on Arterial Inflammation Assessed by Positron Emission Tomography in Patients With PsoriasisCirculation: Cardiovascular Imaging, 2013
- Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular EventsThe American Journal of Medicine, 2011
- Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studiesBritish Journal of Dermatology, 2011
- The First Decade of Biologic TNF Antagonists in Clinical Practice: Lessons Learned, Unresolved Issues and Future Directions2010
- Inflammation in AtherosclerosisJACC, 2009
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2008
- Anti–tumour necrosis factor‐α therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort studyJournal of the European Academy of Dermatology and Venereology, 2007
- The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: A case-control studyJournal of the American Academy of Dermatology, 2007
- Prevalence of cardiovascular risk factors in patients with psoriasisJournal of the American Academy of Dermatology, 2006
- The immune response in atherosclerosis: a double-edged swordNature Reviews Immunology, 2006